380 related articles for article (PubMed ID: 37117135)
41. [Hematological immune-related adverse events of immune checkpoint inhibitors and their management].
Akatsuka Y
Rinsho Ketsueki; 2023; 64(8):782-790. PubMed ID: 37673631
[TBL] [Abstract][Full Text] [Related]
42. Safety of combining radiotherapy with immune-checkpoint inhibition.
Hwang WL; Pike LRG; Royce TJ; Mahal BA; Loeffler JS
Nat Rev Clin Oncol; 2018 Aug; 15(8):477-494. PubMed ID: 29872177
[TBL] [Abstract][Full Text] [Related]
43. Gastrointestinal mucosal toxicities from immune checkpoint inhibitors: Current understanding and future directions.
Dougan M
Immunol Rev; 2023 Sep; 318(1):11-21. PubMed ID: 37455375
[TBL] [Abstract][Full Text] [Related]
44. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A
Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
[TBL] [Abstract][Full Text] [Related]
45. Differential risks of immune-related colitis among various immune checkpoint inhibitor regimens.
Yao J; Li M; Zhang H; Ge Y; Weygant N; An G
Int Immunopharmacol; 2020 Oct; 87():106770. PubMed ID: 32702598
[TBL] [Abstract][Full Text] [Related]
46. Rethinking immune checkpoint blockade: 'Beyond the T cell'.
Liu X; Hogg GD; DeNardo DG
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33468555
[TBL] [Abstract][Full Text] [Related]
47. Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors.
De Martin E; Michot JM; Papouin B; Champiat S; Mateus C; Lambotte O; Roche B; Antonini TM; Coilly A; Laghouati S; Robert C; Marabelle A; Guettier C; Samuel D
J Hepatol; 2018 Jun; 68(6):1181-1190. PubMed ID: 29427729
[TBL] [Abstract][Full Text] [Related]
48. Mechanism and strategies of immunotherapy resistance in colorectal cancer.
Shan J; Han D; Shen C; Lei Q; Zhang Y
Front Immunol; 2022; 13():1016646. PubMed ID: 36238278
[TBL] [Abstract][Full Text] [Related]
49. Targeting the tumor microenvironment to overcome immune checkpoint blockade therapy resistance.
Li Y; Liu J; Gao L; Liu Y; Meng F; Li X; Qin FX
Immunol Lett; 2020 Apr; 220():88-96. PubMed ID: 30885690
[TBL] [Abstract][Full Text] [Related]
50. Cancer immunotherapy-related adverse events: causes and challenges.
Blidner AG; Choi J; Cooksley T; Dougan M; Glezerman I; Ginex P; Girotra M; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Rapoport BL; Anderson R
Support Care Cancer; 2020 Dec; 28(12):6111-6117. PubMed ID: 32857220
[TBL] [Abstract][Full Text] [Related]
51. Immune-related adverse events with immune checkpoint blockade: a comprehensive review.
Michot JM; Bigenwald C; Champiat S; Collins M; Carbonnel F; Postel-Vinay S; Berdelou A; Varga A; Bahleda R; Hollebecque A; Massard C; Fuerea A; Ribrag V; Gazzah A; Armand JP; Amellal N; Angevin E; Noel N; Boutros C; Mateus C; Robert C; Soria JC; Marabelle A; Lambotte O
Eur J Cancer; 2016 Feb; 54():139-148. PubMed ID: 26765102
[TBL] [Abstract][Full Text] [Related]
52. Immune checkpoints and cancer development: Therapeutic implications and future directions.
Mehdizadeh S; Bayatipoor H; Pashangzadeh S; Jafarpour R; Shojaei Z; Motallebnezhad M
Pathol Res Pract; 2021 Jul; 223():153485. PubMed ID: 34022684
[TBL] [Abstract][Full Text] [Related]
53. Exploring novel immune-related toxicities and endpoints with immune-checkpoint inhibitors in non-small cell lung cancer.
Chow LQ
Am Soc Clin Oncol Educ Book; 2013; ():. PubMed ID: 23714523
[TBL] [Abstract][Full Text] [Related]
54. Monitoring immunE DysregulAtion foLLowing Immune checkpOint-inhibitioN (MEDALLION): protocol for an observational cancer immunotherapy cohort study.
Gault A; Hogarth L; Williams KC; Greystoke A; Rajan N; Speight A; Lamb CA; Bridgewood A; Brown-Schofield LJ; Rayner F; Isaacs JD; Nsengimana J; Stewart CJ; Anderson AE; Plummer R; Pratt AG
BMC Cancer; 2024 Jun; 24(1):733. PubMed ID: 38877461
[TBL] [Abstract][Full Text] [Related]
55. Resident Kupffer cells and neutrophils drive liver toxicity in cancer immunotherapy.
Siwicki M; Gort-Freitas NA; Messemaker M; Bill R; Gungabeesoon J; Engblom C; Zilionis R; Garris C; Gerhard GM; Kohl A; Lin Y; Zou AE; Cianciaruso C; Bolli E; Pfirschke C; Lin YJ; Piot C; Mindur JE; Talele N; Kohler RH; Iwamoto Y; Mino-Kenudson M; Pai SI; deVito C; Koessler T; Merkler D; Coukos A; Wicky A; Fraga M; Sempoux C; Jain RK; Dietrich PY; Michielin O; Weissleder R; Klein AM; Pittet MJ
Sci Immunol; 2021 Jul; 6(61):. PubMed ID: 34215680
[TBL] [Abstract][Full Text] [Related]
56. Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer.
Baraibar I; Melero I; Ponz-Sarvise M; Castanon E
Drug Saf; 2019 Feb; 42(2):281-294. PubMed ID: 30649742
[TBL] [Abstract][Full Text] [Related]
57. Immune checkpoint therapy-current perspectives and future directions.
Sharma P; Goswami S; Raychaudhuri D; Siddiqui BA; Singh P; Nagarajan A; Liu J; Subudhi SK; Poon C; Gant KL; Herbrich SM; Anandhan S; Islam S; Amit M; Anandappa G; Allison JP
Cell; 2023 Apr; 186(8):1652-1669. PubMed ID: 37059068
[TBL] [Abstract][Full Text] [Related]
58. Mechanisms of Immune-Related Complications in Cancer Patients Treated with Immune Checkpoint Inhibitors.
König D; Läubli H
Pharmacology; 2021; 106(3-4):123-136. PubMed ID: 32721966
[TBL] [Abstract][Full Text] [Related]
59. Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance.
Martins F; Sofiya L; Sykiotis GP; Lamine F; Maillard M; Fraga M; Shabafrouz K; Ribi C; Cairoli A; Guex-Crosier Y; Kuntzer T; Michielin O; Peters S; Coukos G; Spertini F; Thompson JA; Obeid M
Nat Rev Clin Oncol; 2019 Sep; 16(9):563-580. PubMed ID: 31092901
[TBL] [Abstract][Full Text] [Related]
60. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
